Nature Communications (Oct 2024)

Rumicidins are a family of mammalian host-defense peptides plugging the 70S ribosome exit tunnel

  • Pavel V. Panteleev,
  • Eugene B. Pichkur,
  • Roman N. Kruglikov,
  • Alena Paleskava,
  • Olga V. Shulenina,
  • Ilia A. Bolosov,
  • Ivan V. Bogdanov,
  • Victoria N. Safronova,
  • Sergey V. Balandin,
  • Valeriya I. Marina,
  • Tatiana I. Kombarova,
  • Olga V. Korobova,
  • Olga V. Shamova,
  • Alexander G. Myasnikov,
  • Alexander I. Borzilov,
  • Ilya A. Osterman,
  • Petr V. Sergiev,
  • Alexey A. Bogdanov,
  • Olga A. Dontsova,
  • Andrey L. Konevega,
  • Tatiana V. Ovchinnikova

DOI
https://doi.org/10.1038/s41467-024-53309-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The antimicrobial resistance crisis along with challenges of antimicrobial discovery revealed the vital necessity to develop new antibiotics. Many of the animal proline-rich antimicrobial peptides (PrAMPs) inhibit the process of bacterial translation. Genome projects allowed to identify immune-related genes encoding animal host defense peptides. Here, using genome mining approach, we discovered a family of proline-rich cathelicidins, named rumicidins. The genes encoding these peptides are widespread among ruminant mammals. Biochemical studies indicated that rumicidins effectively inhibited the elongation stage of bacterial translation. The cryo-EM structure of the Escherichia coli 70S ribosome in complex with one of the representatives of the family revealed that the binding site of rumicidins span the ribosomal A-site cleft and the nascent peptide exit tunnel interacting with its constriction point by the conservative Trp23-Phe24 dyad. Bacterial resistance to rumicidins is mediated by knockout of the SbmA transporter or modification of the MacAB-TolC efflux pump. A wide spectrum of antibacterial activity, a high efficacy in the animal infection model, and lack of adverse effects towards human cells in vitro make rumicidins promising molecular scaffolds for development of ribosome-targeting antibiotics.